Structure Therapeutics 주식 (NASDAQ: GPCR)

에 대한 최신 뉴스 Structure Therapeutics (NASDAQ:GPCR) 주식

STRUCTURE THERAPEUTICS INC

Structure Therapeutics

Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.

weight loss ai

Biotech

Equities

News

Health Care

Global

Markets

BHVN

GPCR

RHHBY

스트럭처 테라퓨틱스(NASDAQ:GPCR)의 주식은 비만 치료제 시장에서 잠재적인 승자로 지목되었다. JP모건은 주식에 상당한 상승 잠재력을 부여했다. What Happened: JP모은 생명공학 회사인 스트럭처 테라퓨틱스에 대해 &#34;비중확대(Overweight)&#34; 등급과 목표 주가를 65달러로 이 주식의 커버리지를 시작했다. 이는 현재 수준보다 80%의 잠재적 상승여력을 나타낸다. 비지니스 인사이더(Business Insider)에 따르면 은행은 빠르게 성장하는 GLP-1 체중 감량 약물 시장에서 스트럭처 테라퓨틱스를 주요 업체로 확인했다.

스트럭처 테라퓨틱스 주식은 비만 치료제 시장의 돌파구로 80% 상승 예상: JP모건

Structure Therapeutics Inc. - American Depositary Shares

Structure Therapeutics Inc

<a href="https://www.youtube.com/watch?v=z-16fImZoEc">https://www.youtube.com/watch?v=z-16fImZoEc</a>
&nbsp;

General

BNTX

MRNA

NVAX

U.S. CDC Advisory Panel Votes 5-1 In Favor Of Children 18 Years & Younger Receiving Seasonal Flu Vaccine Only In Single Dose Forms That Are Free From Thimerosal; Of Pregnant Women Receiving Seasonal Flu Vaccine Only In Single Dose Forms That Are Free From Thimerosal; Of All Adults Receiving Seasonal Flu Shot Only In Single Dose Forms That Are Free From Thimerosal

U.S. CDC Vaccine Advisory Panel Votes 7-0 In Favor Of Adding Preventive RSV Therapies To Vaccines For Children Resolution

<a href="https://www.youtube.com/watch?v=z-16fImZoEc" title="https://www.youtube.com/watch?v=z-16fImZoEc">https://www.youtube.com/watch?v=z-16fImZoEc</a>

U.S. CDC Vaccine Advisory Panel Votes 5-2 In Favor Of Merck's RSV Antibody Drug For Infants 8 Months Or Younger

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining over 100 points on Thursday.
The Dow traded up 0.82% to 43,335.29 while the NASDAQ gained 0.69% to 20,110.81. The S&amp;P 500 also rose, gaining, 0.66% to 6,132.29.
Check This Out: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/46113083/amd-taiwan-semiconductor-manufacturing-cnbc-final-trades">AMD, Taiwan Semiconductor And A Financial Stock On CNBC&#8217;s &#8216;Final Trades&#8217;</a>
Leading and Lagging Sectors Materials shares jumped by 0.9% on Thursday.
In trading on Thursday, real estate stocks fell by 1%.
Top Headline
Walgreens Boots Alliance Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) on Thursday reported better-than-expected earnings for the third quarter on Thursday.
The company posted third-quarter sales of $38.99 billion, up 7.2% year over year (+6.9% on constant currency), beating the consensus of $36.84 billion, reflecting sales growth in the U.S. Retail Pharmacy and International segments. Adjusted EPS was 38 cents, down from 63 cents a year ago, beating the consensus of 34 cents, according to data from Benzinga Pro.
Walgreens Boots Alliance withdrew its 2025 guidance as part of the M&amp;A deal with Sycamore Partners. The merger is expected to close in the fourth quarter of calendar year 2025.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Cyngn Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) shares shot up 277% to $18.83 after the company announced it partnered with Nvidia to showcase its autonomous industrial vehicles at Automatica 2025.</li>
<li>Shares of Ascent Solar Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTI#NASDAQ">ASTI</a>) got a boost, surging 113% to $2.4799 after the company entered into a collaborative agreement with NASA.</li>
<li>Worthington Steel, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WS#NYSE">WS</a>) shares were also up, gaining 13% to $29.69 as the company reported stronger-than-expected financial results for the fourth quarter.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Globavend Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GVH#NASDAQ">GVH</a>) shares dropped 74% to $0.1835 after the company announced the pricing of a $15 million offering of 21,739,130 shares at $0.69 per share.</li>
<li>Shares of Altimmune, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) were down 56% to $3.4133 after the company announced topline results from the IMPACT Phase 2b trial of Pemvidutide in the treatment of MASH.</li>
<li>Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVPH#NASDAQ">RVPH</a>) was down, falling 54% to $0.3502 after the company announced a $10 million public offering of 20 million shares and dual warrants at a combined price of $0.50 per share and accompanying warrants.</li>
</ul>
Commodities In commodity news, oil traded up 1.3% to $65.79 while gold traded down 0.2% at $3,335.10.
Silver traded up 0.9% to $36.420 on Thursday, while copper rose 3% to $5.1200.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 rose 0.01%, while Spain's IBEX 35 Index rose 0.03%. London's FTSE 100 rose 0.23%, Germany's DAX 40 gained 0.38% and France's CAC 40 slipped 0.11% during the session.
Asia Pacific Markets
Asian markets closed mixed on Thursday, with Japan's Nikkei gaining 1.65%, Hong Kong's Hang Seng Index falling 0.61%, China's Shanghai Composite falling 0.22% and India's BSE Sensex rising 1.21%.
Economics
<ul class="wp-block-list">
<li>The U.S. economy shrank at an annualized rate of 0.5% in the first quarter, compared to a 0.2% decline as per the second estimate.</li>
<li>U.S. initial jobless claims declined by 10,000 from the previous week to 236,000 in the week ended June 21.</li>
<li>U.S. durable goods orders climbed by 16.4% month-over-month to $343.6 billion in May compared to a revised 6.6% decline in April.</li>
<li>The U.S. trade deficit in goods increased to $96.6 billion in May from $87.0 billion in the previous month, and versus market estimates of an $88.5 billion gap.</li>
<li>The Chicago Fed National Activity Index rose to –0.28 in May compared to a revised reading of –0.36 in April.</li>
<li>U.S. wholesale inventories declined 0.3% month-over-month to $905.4 billion in May following a revised 0.1% gain in April.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/46108846/nike-likely-to-report-lower-q4-earnings-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call">Nike Likely To Report Lower Q4 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a></li>
</ul>
Photo: Shutterstock

Intraday Update

Movers

Trading Ideas

ASTI

RVPH

Crude Oil Gains Over 1%; Walgreens Posts Upbeat Earnings

Live Nation Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>) has outperformed the market over the past 5 years by 12.28% on an annualized basis producing an average annual return of 26.93%. Currently, Live Nation Entertainment has a market capitalization of $34.40 billion. 
Buying $1000 In LYV: If an investor had bought $1000 of LYV stock 5 years ago, it would be worth $3,297.58 today based on a price of $146.94 for LYV at the time of writing.
<h3>Live Nation Entertainment's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750956311_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Live Nation Entertainment 5 Years Ago Would Be Worth Today

WIIM

MLKN

MillerKnoll shares are trading higher after the company reported better-than-expected Q4 EPS and sales.

Piper Sandler analyst Biren Amin reiterates Context Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTX#NASDAQ">CNTX</a>) with a Overweight and lowers the price target from $4.5 to $4.

Price Target

Reiteration

Analyst Ratings

CNTX

Piper Sandler Reiterates Overweight on Context Therapeutics, Lowers Price Target to $4

Core Scientific, Inc. - Class A Common Stock

CORZ

Core Scientific Shares Resume Trade

<a href="https://www.youtube.com/watch?v=z-16fImZoEc " title="https://www.youtube.com/watch?v=z-16fImZoEc ">https://www.youtube.com/watch?v=z-16fImZoEc&nbsp;</a>
&nbsp;

U.S. CDC Advisory Panel Votes 6-0 In Favor Of Annual Flu Vaccinations For Those Aged 6 Months And Above And Do Not Have Any Contraindications

Piper Sandler analyst Nathan Race reiterates Bridgewater Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BWB#NASDAQ">BWB</a>) with a Overweight and raises the price target from $18 to $19.

Piper Sandler Reiterates Overweight on Bridgewater Bancshares, Raises Price Target to $19

Plug Power Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) shares are surging on Thursday, staging a strong recovery after a significant sell-off last week.
What To Know: The rebound comes following the hydrogen fuel cell company&#8217;s participation in <a href="https://www.benzinga.com/pressreleases/25/06/g46070260/plug-executive-leadership-to-participate-in-investor-conferences-in-new-york-and-london">two key investor conferences</a>, in what investors are likely interpreting as a proactive approach to engaging with the financial community.
On Tuesday, Plug executives presented at the J.P. Morgan Energy, Power, Renewables &amp; Mining Conference in New York. CEO Andy Marsh also participated in the Roth 15th Annual London Conference on Wednesday. The company stated these appearances reinforced its strategic priorities and long-term growth plans.
The positive momentum this week follows a <a href="https://www.benzinga.com/trading-ideas/movers/25/06/46000425/whats-going-on-with-plug-power-stock-11">turbulent prior week</a> for the green energy sector. Plug Power&#8217;s stock, along with its peers, tumbled last week after a draft tax bill in the U.S. Senate proposed an accelerated phase-out of clean energy tax credits established under the Inflation Reduction Act.
This news overshadowed <a href="https://www.benzinga.com/trading-ideas/movers/25/06/45906821/plug-power-plug-stock-surges-59-over-past-week-whats-driving-the-rally">positive developments</a> for Plug earlier in June, including an expanded partnership for a major green chemical plant in Uzbekistan and significant open-market share purchases by its CFO, Paul Middleton. 
This week&#8217;s rebound suggests investor focus is shifting back to the company&#8217;s growth prospects despite potential policy headwinds.
Price Action: According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, PLUG shares are trading higher by 15.1% to $1.25 Thursday morning. The stock has a 52-week high of $3.34 and a 52-week low of $0.69.
Read Also: <a href="https://www.benzinga.com/quote/PLUG/analyst-ratings">Plug Power Analyst Ratings</a>
<h2 class="wp-block-heading">How To Buy PLUG Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Plug Power&#8217;s case, it is in the Industrials sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
Image: Shutterstock

PLUG

What's Going On With Plug Power Stock?

<a href="https://www.fitchratings.com/research/corporate-finance/boeing-recovery-supports-suppliers-airlines-eetc-issuances-26-06-2025#:~:text=Fitch%20Ratings%2DToronto%2D26%20June,or%202026%2C%20Fitch%20Ratings%20says" title="https://www.fitchratings.com/research/corporate-finance/boeing-recovery-supports-suppliers-airlines-eetc-issuances-26-06-2025#:~:text=Fitch%20Ratings%2DToronto%2D26%20June,or%202026%2C%20Fitch%20Ratings%20says">https://www.fitchratings.com/research/corporate-finance/boeing-recovery-supports-suppliers-airlines-eetc-issuances-26-06-2025#:~:text=Fitch%20Ratings%2DToronto%2D26%20June,or%202026%2C%20Fitch%20Ratings%20says</a>.

Fitch Ratings Says Boeing's Production Improvement Enhances Stability Across Aerospace Supply Chain, Can Support Recovery In EETC Issuances Starting 2h25/2026; Expects 737max Production Run Rates To Reach 38 Per Month In Q3; Expects Air Travel Demand To Soften But Does Not Anticipate Significant Order Deferrals/Cancellations

Piper Sandler analyst James Callahan reiterates AppLovin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) with a Overweight and raises the price target from $455 to $470.

Piper Sandler Reiterates Overweight on AppLovin, Raises Price Target to $470

Platinum is staging a spectacular rally this year, rising more than 30% in June alone and hitting $1,390 per ounce—its highest level since September 2014—putting it on track for its best <a href="https://www.benzinga.com/topic/metals">monthly performance since 1986.</a>
The precious metal, closely tracked by the GraniteShares Platinum Shares ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTM#NYSE">PLTM</a>), has gained over 50% year-to-date, more than doubling the returns seen in gold, which is up 25%, and silver, which is up 24%, as investors chase platinum amid expectations of continued structural deficits.
Elevated platinum prices are poised to deliver windfall profits for key mining companies with heavy exposure to the metal, many of which have already begun a bull market.
<h3 class="wp-block-heading">Chart: Platinum Is On Track For Best-Performing Month Since 1986</h3>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="528" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26102448/image-413-1024x528.png" alt="" class="wp-image-963434" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26102448/image-413-1024x528.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26102448/image-413-300x155.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26102448/image-413-768x396.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26102448/image-413-1536x792.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26102448/image-413-2048x1056.png 2048w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h3 class="wp-block-heading">What's Fueling The Platinum Rally?</h3>
According to the World Platinum Investment Council, the rally is underpinned by long-standing supply shortages. 
The group projects that platinum market deficits will persist through 2029, averaging 727,000 ounces annually from 2025 to 2029, equivalent to approximately 9% of average demand.
"The platinum investment case remains compelling," the council said, highlighting ongoing shortfalls driven by falling above-ground stockpiles, constrained supply from key producing regions, and rising demand from China's jewelry sector.
These market conditions are largely unaffected by short-term price levels.
Both supply and demand remain highly inelastic, which suggests further upside pressure could continue if investor sentiment remains bullish and physical supply struggles to meet demand.
De-dollarization efforts and broader concerns over global macroeconomic stability have also played a role. 
As gold and silver rallied on those themes earlier in the year, platinum and palladium were seen as laggards, attracting "catch-up" trades from institutional and retail investors.
<h2 class="wp-block-heading">What Are the Platinum Downside Risks Going Forward?</h2>
Goldman Sachs sees some downside risks for platinum. In a note shared on June 11, analyst Lina Thomas said, "Chinese buying appears highly price sensitive and tends to fall when prices are high." 
She also noted that China's pivot to electric vehicles is reducing long-term demand for platinum in catalytic converters, while increasing scrap supply as internal combustion engine cars are retired.
"In the West, our Autos equity analysts expect the ICE and hybrid vehicle fleet to remain relatively stable," Thomas added.
On the supply side, Goldman expects stable to slightly higher global production, mainly from South Africa, which supplies 70% of the world's platinum. 
Unless power outages recur, output is unlikely to decline, as platinum is mined primarily as a by-product and production is less responsive to price fluctuations due to its high fixed costs.
<h2 class="wp-block-heading">Who Are The Top Platinum Producers?</h2>
The global platinum market is concentrated in southern Africa, primarily in South Africa and Zimbabwe. 
Anglo American Platinum Ltd. is the world's largest platinum producer and a subsidiary of Anglo American plc (OTCPK: NGLOD). Its operations span South Africa and are heavily exposed to fluctuations in platinum pricing.
Impala Platinum Holdings Ltd. (OTCPK: IMPUF), or Implats, is the second-largest global producer, with significant assets in South Africa and Zimbabwe.
D/B/A Sibanye Stillwater Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SBSW#NYSE">SBSW</a>) operates in both South Africa and the U.S., with a diversified portfolio across the platinum group metals (PGMs). 
Sibanye Stillwater is the only platinum-focused miner listed on a major U.S. exchange, trading under the ticker SBSW.
Northam Platinum Ltd. (OTCPK: NPLTF) is a mid-tier South African producer with growing mining and processing assets, known for its operational focus on high-grade ore bodies.
African Rainbow Minerals Ltd. (OTCPK: AFBOF) holds significant stakes in platinum group metals projects alongside interests in ferrous and base metals, offering exposure to multiple commodity cycles.
Glencore plc (OTCPK: GLNCY), while not a pure-play platinum producer, maintains platinum exposure through joint ventures and partnerships in southern Africa.
These producers have surged in tandem with platinum's rally, with several posting double-digit gains in June. With market deficits forecast to persist through 2029, investor interest could remain strong, especially if prices stay above $1,300.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/46099022/best-ai-stocks-nvidia-semiconductors-top-performers">The AI Rally Just Flipped—These Stocks Are Now Outgunning Nvidia </a></li>
</ul>
Photo: yMediaStock/Shutterstock

Analyst Color

Emerging Markets

Specialty ETFs

Commodities

Econ #s

Economics

ETFs

AFBOF

GLNCY

IMPUF

NGLOD

First Trust ISE Global Platinum Index Fund

PLTM

SBSW

Platinum's Biggest Rally In 40 Years: These 6 Mining Stocks Could Be Top Gainers

KKR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) has outperformed the market over the past 5 years by 18.95% on an annualized basis producing an average annual return of 33.61%. Currently, KKR has a market capitalization of $115.29 billion. 
Buying $100 In KKR: If an investor had bought $100 of KKR stock 5 years ago, it would be worth $435.73 today based on a price of $129.45 for KKR at the time of writing.
<h3>KKR's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750955657_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

SBEV

Splash Beverage Group Shares Resume Trade Following Circuit Breaker Halt

Piper Sandler analyst Anna Andreeva initiates coverage on Amer Sports (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AS#NYSE">AS</a>) with a Overweight rating and announces Price Target of $45.

Initiation

Piper Sandler Initiates Coverage On Amer Sports with Overweight Rating, Announces Price Target of $45

CRWV

CoreWeave shares are trading lower after the Wall Street Journal reported the company is in talks to acquire Core Scientific.

Core Scientific shares are trading higher after the Wall Street Journal reported that CoreWeave is in talks to acquire the company.

<a href="https://www.benzinga.com/25/03/44539746/31-of-u-s-workers-have-a-side-hustle-but-which-professions-are-the-most-likely-to-take-on-side-gigs">Side hustles </a>can provide an extra source of income, a second job or a part-time job with flexible hours for those in need of any of the following.
While many side hustles can take time to pay off, a 27-year-old who made $700,000 in one year shared advice on how to look for side gigs and make them pay off.
What Happened:&nbsp;Twenty-seven-year-old&nbsp;Cody Berman&nbsp;has been trying out different side hustles over the years. Included in his history of side hustles are some that many people and investors are familiar with, including selling online courses on how to sell items on&nbsp;Etsy Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETSY#NASDAQ">ETSY</a>)&nbsp;and how to make money<a href="https://www.benzinga.com/news/23/06/32882243/she-turned-her-neighbors-barn-into-an-airbnb-now-she-generates-nearly-3m-a-year-from-rentals-she-doe" target="_blank" rel="noreferrer noopener">&nbsp;renting out properties</a>&nbsp;on&nbsp;Airbnb Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>).
Berman told&nbsp;<a href="https://www.cnbc.com/2023/07/22/side-hustle-expert-cody-berman-on-how-to-find-easiest-ones-for-you.html" target="_blank" rel="noreferrer noopener">CNBC&nbsp;</a>that his first official side gig was a disc golf company he founded his freshman year in college. That job led to finding more and more side gigs that brought in around $1,500 to $1,800 in monthly income.
"I started getting some freelance writing gigs during college," Berman said. "Also did some tutoring, podcast editing, video editing, running affiliate marketing campaigns."
With years of experience running side hustles, Berman shared advice on the easiest way for others to get started.
Read Also: <a href="https://www.benzinga.com/personal-finance/entrepreneurship/25/06/46043812/this-womans-eye-for-hidden-treasures-now-earns-her-10k-a-month">This Woman&#8217;s Eye For Hidden Treasures Now Earns Her $10K A Month</a>
Advice on Side Hustles:&nbsp;Berman offers two key pieces of advice for anyone new in the side hustle game, and looking to get started.
"Look at the skills that you have," is the first piece of advice from Berman.
The entrepreneur says the easiest side hustle for each person is going to be different depending on their skills. Berman was attracted to content creation early with podcast editing and video editing as he had experience with editing tools.
Berman said skills that people could have could be writing, graphic design, customer service and more. Berman also said it's important to look at assets that you own, which could be a car, a home, or a bike, all items that could be rented out or used to make money with side hustles.
"There's always someone who's willing to pay" is the second piece of advice from Berman. The entrepreneur recommends checking out freelance sites like Fiverr, Upwork and TaskRabbit to see how different tasks and jobs pay.
"There's an unlimited number of opportunities now with the internet and all these different apps."
Berman also said a side hustle that people are willing to pay for often today is social media. The entrepreneur suggested looking at local businesses that you might be familiar with, who may be in need of service.
"There's landscaping companies, there's plumbing companies, there's electricians that have no idea what they're doing on social media. If you come to them with a decent proposal, you can run social media for them."
If you enjoyed this story, check out more coverage on entrepreneurship and stories of success&nbsp;<a href="https://www.benzinga.com/topic/benzinga-inspire" target="_blank" rel="noreferrer noopener">with Benzinga Inspire.</a>
This article was previously published by Benzinga and has been updated.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/personal-finance/entrepreneurship/25/06/46026335/from-side-hustle-to-big-business-young-entrepreneur-makes-354000-a-month">How 25-Year-Old Tried 23 Side Hustles And Finally Built A $350,000/Month Business</a></li>
</ul>
Image via Just dance/Shutterstock

Entrepreneurship

Success Stories

ABNB

ETSY

How 27-Year-Old Turned Side Hustles Into $700K—And His 2 Rules For Getting Started

Management

Press Releases

Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D. as Chief Development Officer

Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2024

Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity

Earnings

Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights

Structure Therapeutics to Participate in the Jefferies London Healthcare Conference

Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity

Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences

Structure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Highlights

Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671

Amphastar Pharmaceuticals, Inc. - Common Stock

Amphastar Pharma

ANI Pharmaceuticals

BGM Group

Belite Bio, Inc - American Depositary Shares

Belite Bio

Collegium Pharmaceutical, Inc. - Common Stock

Collegium Pharmaceutical

Cormedix

Enliven Therapeutics, Inc. - Common Stock

Enliven Therapeutics

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics

EyePoint Pharmaceuticals, Inc. - Common Stock

EyePoint Pharmaceuticals

GH Research

Harmony Biosciences Holdings, Inc. - Common Stock

Harmony Biosciences Hldgs

Harrow

Indivior

Innoviva

LENZ Therapeutics

Ligand Pharmaceuticals Incorporated - Common Stock

Ligand Pharmaceuticals

Liquidia

Ocular Therapeutix

Phibro Animal Health Corporation - Class A Common Stock

Phibro Animal Health

Pacira BioSciences

Supernus Pharmaceuticals, Inc. - Common Stock

Supernus Pharmaceuticals

Tarsus Pharmaceuticals, Inc. - Common Stock

Tarsus Pharmaceuticals

Trevi Therapeutics

Wave Life Sciences Ltd. - Ordinary Shares

WAVE Life Sciences

Xeris Biopharma Holdings, Inc. - Common Stock

Xeris Biopharma Holdings

Cantor Fitzgerald

JMP Securities

HC Wainwright & Co.

Citigroup

Citizens Capital Markets

스트럭처 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPCR#NASDAQ">GPCR</a>)의 주식은 비만 치료제 시장에서 잠재적인 승자로 지목되었다. JP모건은 주식에 상당한 상승 잠재력을 부여했다.
What Happened: JP모은 생명공학 회사인 스트럭처 테라퓨틱스에 대해 &#8220;비중확대(Overweight)&#8221; 등급과 목표 주가를 65달러로 이 주식의 커버리지를 시작했다. 이는 현재 수준보다 80%의 잠재적 상승여력을 나타낸다. 비지니스 인사이더(Business Insider)에 따르면 은행은 빠르게 성장하는 GLP-1 체중 감량 약물 시장에서 스트럭처 테라퓨틱스를 주요 업체로 확인했다.
스트럭처 테라퓨틱스는 GLP-1 체중 감량 시장을 겨냥해 고안된 경구용 알약인 &#8216;1290&#8217;이라는 약물 후보를 개발하고 있다. 이 약물은 잠재적으로 경쟁사보다 1~2년 앞서 시장에 출시될 수 있는 소분자 제제를 기반으로 한다.
이 약은 다른 경구용 체중 감량 약물 후보와 차별화되어 안전성에 큰 우려가 없는 환자에게 상당한 체중 감량 효과를 제공할 것으로 기대된다.
"우리는 전례 없이 큰 시장에서 구강 시장에서 GPCR의 시장 점유율이 시간이 지남에 따라 5%에 접근할 수 있다고 생각한다. 전체적으로 우리는 1290/스트럭처가 T2D/비만 시장에 참여하려는 대규모 바이오제약 회사들에게 매력적인 파트너십 기회가 될 수 있다고 생각한다"라고 JP모건이 말했다.
JP모건은 스트럭처 테라퓨틱스의 경구용 GLP-1 체중 감량 약물 후보가 2035년까지 10억 달러 이상의 최고 매출을 올릴 수 있을 것으로 믿고 있다. 이 회사는 2023년 2월에 상장되었다.
참조: <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38910906/bitcoin-dogecoin-ethereum-retrace-on-profit-taking-by-retail-investors-analyst-predicts-pa?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">비트코인, 도지코인, 이더리움은 소매 투자자들의 이익 실현에 하락</a>
Why It Matters: 비만 치료제 시장은 중요한 발전을 보이고 있다. 최근 로슈(OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>)은 이중 GLP-1/GIP 수용체 작용제 CT-388의 1b상 시험에서 유망한 결과를 발표하여 비만 치료 시장에서 <a href="https://www.benzinga.com/general/biotech/24/05/38878582/roche-to-ride-booming-obesity-treatment-market-with-newly-acquired-drug-candidate">상당한 잠재력</a>을 나타냈다.
또한 일라이 릴리(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)는 중국에서 당뇨병 치료제 티르제파티드(tirzepatide)에 대한 승인을 확보하여 중요한 아시아 시장에서 노보 노디스크 A/S(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>)와의 <a href="https://www.benzinga.com/general/biotech/24/05/38941485/eli-lilly-secures-china-nod-for-popular-weight-lossdiabetes-drug-tirzepatide">경쟁</a>이 치열해질 수 있는 발판을 마련했다.
앞서 바이오헤븐(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHVN#NYSE">BHVN</a>)은 체중 감량을 돕는 동시에 근육 손실을 예방할 수 있는 실험 약물인 탈데프그로벱 알파(taldefgrobep alfa)(BHVN-2000)를 통해 비만 치료제 시장에 대한 <a href="https://www.benzinga.com/general/biotech/24/03/37942782/obesity-drug-landscape-has-a-contender-from-biohaven-ceo-highlights-different-approach-amid-stiff">다른</a> 접근 방식을 강조했다.
다음 읽기: <a href="https://www.benzinga.com/tech/24/05/38919616/apples-groundbreaking-iphone-16-could-spark-another-stock-surge-building-on-an-800-growth-over-the-l?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">애플, 6월 WWDC에서 아이폰 13 시리즈 공개 예고</a>
AI를 통해 생산된 이미지
<hr class="wp-block-separator has-alpha-channel-opacity" />
Benzinga Neuro의 기술, <a href="https://www.benzinga.com/topic/Kaustubh-Bagalkote" target="_blank" rel="noreferrer noopener">Kaustubh Bagalkote</a> 편집
<hr class="wp-block-separator has-alpha-channel-opacity" />
GPT-4 기반의 Benzinga Neuro 콘텐츠 생성 시스템은 광벤짜 생태계의 네이티브 데이터, API 등을 활용하여 포괄적이고 시의적절한 이야기를 제공합니다. <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">더 알아보기</a>.
<hr class="wp-block-separator has-alpha-channel-opacity" />

Comments

Structure Therapeutics

뉴스

에 대한 최신 뉴스 Structure Therapeutics (NASDAQ:GPCR) 주식

수요일, 5월 22, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌